Ricks said Eli Lilly had yet to begin what the company calls "demand-stimulating activities," or advertising and promoting, for Zepbound. The drugmaker will start those efforts in November, he said.

Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.

Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...

Eli Lilly and Company (NYSE:LLY) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On July 30, the company ...

Eli Lilly and Company LLY reported third-quarter 2024 adjusted earnings per share (“EPS”) of $1.18, which missed the Zacks Consensus Estimate of $1.52 per share. In the year-ago quarter, the ...

Mounjaro and Zepbound helped drive the US drugmaker's total Q2 revenue to $15.56bn, up 38% from the same period last year. In a conference call, Eli Lilly CEO David Ricks acknowledged the role the two ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors remain unconvinced.

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Eli Lilly and Co. reported strong second-quarter results, beating Wall Street estimates and prompting the company to raise its full-year revenue forecast by $3 billion.

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...